Who We Are

Leadership

Our leadership team brings diverse experience in research, clinical development, business operations, and patient care to Seagen. Their expertise and guidance are critical to advancing our mission to make a meaningful difference in cancer care.

Seagen CMO - Roger Dansey, M.D.

Roger Dansey, M.D.

Interim Chief Executive Officer
and Chief Medical Officer

MANAGEMENT TEAM

Seagen CTO - Vaughn Himes, Ph.D.
 

Vaughn Himes, Ph.D.

Chief Technical Officer

Seagen CFO - Todd Simpson
 

Todd Simpson

Chief Financial Officer

Seagen SVP Corporate Development - Natasha Hernday
 

Natasha Hernday

Executive Vice President, Corporate Development and Alliance Management

Chief Legal Officer - Jean Liu, J.D.
 

Jean Liu, J.D.

Chief Legal Officer

Seagen EVP Commercial International - Lee Heeson
 

Lee Heeson

Executive Vice President, Commercial International

Seagen Human Resources - Christopher Pawlowicz
 

Christopher Pawlowicz

Executive Vice President, Human Resources

Seagen EVP Commercial U.S. - Charles (Chip) Romp
 

Charles (Chip) Romp

Executive Vice President, Commercial U.S.

BOARD OF DIRECTORS

Felix Baker, Ph.D.

+

Dr. Baker has served on the Board of Directors for Seagen since July 2003, as our lead independent director since February 2005, and was appointed Chair of the Board in May 2022. He is also the founder of Baker Bros. Advisors LP, an advisory firm focused on investments in life science and biotechnology companies. As a board member and investor in many successful biotechnology companies, Dr. Baker’s experience and vision in investment and company building adds significant value to Seagen’s strategy. 

Dr. Baker holds a B.S. and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school. He serves as a member of the board of directors of Kiniksa Pharmaceuticals, Ltd., Kodiak Sciences Inc., IGM Biosciences, Inc., and Talis Biomedical Corporation.

David Gryska

+

Mr. Gryska joined our Board of Directors in March 2005. With many years of experience as a senior financial executive at life sciences and biotechnology companies, he brings expertise in financing, global expansion, and other strategic transactions to our board. Mr. Gryska is the chair of our Audit Committee, utilizing his extensive knowledge of accounting principles, financial reporting rules and regulations, tax compliance, and financial reporting processes at publicly traded corporations. 

Throughout his career, Mr. Gryska served as a Chief Financial Officer at Incyte Corporation, Celgene Corporation, Scios Inc., and Cardiac Pathways Corporation. He was the Executive Vice President and Chief Financial Officer of Incyte Corporation. 

Mr. Gryska holds an M.B.A. from Golden Gate University and a B.A. in Accounting and Finance from Loyola University. He serves as a member of the board of directors for Aerie Pharmaceuticals, Inc.

Ted Love, M.D.

+

Dr. Love joined our Board of Directors in August 2020. With more than two decades of leadership and management experience in the pharmaceutical industry, in addition to prior experience as a practicing physician, Dr. Love brings both strong business expertise and knowledge of patient perspectives to our Board of Directors.

Dr. Love is the President and Chief Executive Officer of Global Blood Therapeutics, Inc. Previously, he was Executive Vice President, Research and Development and Technical Operations at Onyx Pharmaceuticals, Inc.

Dr. Love holds a B.A. in Molecular Biology from Haverford College and an M.D. from Yale Medical School. Dr. Love also serves on the boards of Global Blood Therapeutics, Inc. and Royalty Pharma plc.

John Orwin

+

Mr. Orwin joined the Seagen Board of Directors in January 2014. With many years of experience as a senior executive at leading pharmaceutical and biotechnology companies, he brings a strong understanding of the industry and the challenges we must meet to continue developing and commercializing product candidates. 

Mr. Orwin is the President and Chief Executive Officer of Atreca, Inc. Previously, he was the Chief Executive Officer of Relypsa, Inc., now an affiliate of Vifor Pharma AG. Mr. Orwin also held multiple leadership roles at Affymax, Inc., including Chief Executive Officer, President, and Chief Operating Officer. Earlier in his career, he led the BioOncology Business Unit at Genentech, Inc. and was the Franchise Vice President of Tibotec Therapeutics at Johnson & Johnson.  

Mr. Orwin holds an M.B.A. from the Stern School of Business at New York University and a B.A. in Economics from Rutgers University. He serves as a member of the board of directors for Atreca, Inc. and Travere Therapeutics, Inc.

Alpna Seth, Ph.D.

+

Dr. Seth joined our Board of Directors in March 2018. With more than 20 years of global experience in the biotechnology industry, she brings a breadth of expertise in drug development, commercialization, and international operations to Seagen. 

Dr. Seth is the Chief Executive Officer and President of Nura Bio, a biopharmaceutical company focused on the discovery of novel neuroprotective drugs. Previously, she was Chief Operating Officer of Vir Biotechnology, Inc. and the Senior Vice President and Global Head of the Biosimilars Global Business Unit at Biogen Inc. Before joining Biogen, Dr. Seth was a management consultant in the healthcare industry.  

Dr. Seth earned her Ph.D. in Biochemistry and Molecular Biology from the University of Massachusetts Medical School and completed post-doctoral research at Harvard University in Immunology and Structural Biology. She is a graduate of Harvard Business School’s Advanced Management Program (AMP) and has served as a guest lecturer at Harvard Business School and Harvard Medical School. Dr. Seth serves as a member of the board of directors for Bio-Techne Corporation.

Nancy Simonian, M.D.

+

Dr. Simonian is a seasoned senior executive in biotechnology who joined the Seagen Board of Directors in March 2012. She possesses a deep understanding of the biotechnology industry and the development and commercialization of product candidates. As a physician, Dr. Simonian also brings important insight into patient perspectives to our Board of Directors. 

Dr. Simonian is the Chief Executive Officer of Syros Pharmaceuticals, Inc. Previously, she was the Chief Medical Officer at Millennium Pharmaceuticals, Inc. and the Vice President of Clinical Development at Biogen. 

Dr. Simonian holds an M.D. from the University of Pennsylvania Medical School and a B.A. in Biology from Princeton University. She serves as a member of the board of directors for Syros Pharmaceuticals, Inc.

Daniel Welch

+

Mr. Welch has served on the Board of Directors for Seagen since June 2007. With a background in global commercial development and experience as a senior executive at biotechnology companies, he contributes invaluable strategic insight to our senior management and Board of Directors. 

Previously, Mr. Welch was an Executive Partner at Sofinnova Ventures and the Chairman and Chief Executive Officer of two publicly traded biotechnology companies, InterMune, Inc. and Triangle Pharmaceuticals, Inc.  

Mr. Welch holds an M.B.A. from the University of North Carolina and a B.A. from the University of Miami. He serves as Chairman of the Board for Ultragenyx Pharmaceuticals Inc., as well as Nuvation Bio Inc.

>